Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2014, Article ID 479246, 15 pages
http://dx.doi.org/10.1155/2014/479246
Review Article

Recent Advances in Delivery Systems and Therapeutics of Cinnarizine: A Poorly Water Soluble Drug with Absorption Window in Stomach

Department of Pharmaceutics, Rajiv Academy for Pharmacy, N.H. No. 2, P.O. Chattikara, Mathura, Uttar Pradesh 281001, India

Received 23 July 2014; Accepted 15 October 2014; Published 13 November 2014

Academic Editor: Juan M. Irache

Copyright © 2014 Smita Raghuvanshi and Kamla Pathak. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Kumar and C. Singh, “A study on solubility enhancement methods for poorly water soluble drugs,” The American Journal of Pharmacological Sciences, vol. 1, no. 4, pp. 67–73, 2013. View at Google Scholar
  2. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao, “Nanonization strategies for poorly water-soluble drugs,” Drug Discovery Today, vol. 16, no. 7-8, pp. 354–360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. C.-H. Gu, D. Rao, R. B. Gandhi, J. Hilden, and K. Raghavan, “Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility,” Journal of Pharmaceutical Sciences, vol. 94, no. 1, pp. 199–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. H. Fagerberg, O. Tsinman, N. Sun, K. Tsinman, A. Avdeef, and C. A. S. Bergström, “Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media,” Molecular Pharmaceutics, vol. 7, no. 5, pp. 1419–1430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Patel, P. Jayvadan, T. Rashmin et al., “Improvement of solubility of cinnarizine by using solid dispersion technique,” International Research Journal of Pharmacy, vol. 1, pp. 127–131, 2010. View at Google Scholar
  6. B.-Q. Li, G.-Q. Yang, S.-H. Fang et al., “Effect of route of administration on the pharmacokinetics and toxicokinetics of cinnarizine in dogs,” European Journal of Pharmaceutical Sciences, vol. 40, no. 3, pp. 197–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Kornhuber, A. W. Henkel, T. W. Groemer et al., “Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system,” Journal of Cellular Physiology, vol. 224, no. 1, pp. 152–164, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Kariya, S. Isozaki, S. Narimatsu, and T. Suzuki, “Oxidative metabolism of cinnarizine in rat liver microsomes,” Biochemical Pharmacology, vol. 44, no. 7, pp. 1471–1474, 1992. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Kariya, S. Isozaki, K. Uchino, T. Suzuki, and S. Narimatsu, “Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes,” Biological and Pharmaceutical Bulletin, vol. 19, no. 11, pp. 1511–1514, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Narimatsu, S. Kariya, S. Isozaki et al., “Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes,” Biochemical and Biophysical Research Communications, vol. 193, no. 3, pp. 1262–1268, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. S. C. Sweetman, Martindle: The Complete Drug Reference, The Pharmaceutical Press, London, UK, 33rd edition, 2002.
  12. D. Turner, Y. Lurie, Y. Finkelstein et al., “Pediatric cinnarizine overdose and toxicokinetics,” Pediatrics, vol. 117, no. 5, pp. e1067–e1069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. G. López, M. A. Moro, C. F. Castillo, C. R. Artalejo, and A. G. Garcia, “Variable, voltage-dependent, blocking effects of nitrendipine, verapamil, diltiazem, cinnarizine and cadmium on adrenomedullary secretion,” British Journal of Pharmacology, vol. 96, no. 3, pp. 725–731, 1989. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Broekaert and T. Godfraind, “A comparison of the inhibitory effect of cinnarizine and papaverine on the noradrenaline- and calcium-evoked contraction of isolated rabbit aorta and mesenteric arteries,” European Journal of Pharmacology, vol. 53, no. 3, pp. 281–288, 1979. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Shi, H. Chen, Y. Cui, and X. Tang, “Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion,” International Journal of Pharmaceutics, vol. 373, no. 1-2, pp. 147–155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Haasler, G. Homann, T. A. Duong Dinh, E. Jüngling, M. Westhofen, and A. Lückhoff, “Pharmacological modulation of transmitter release by inhibition of pressure-dependent potassium currents in vestibular hair cells,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 380, no. 6, pp. 531–538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. G. Pukhal'skaya, O. A. Kolosova, M. Y. Men'shikov, and A. M. Vein, “Effects of calcium antagonists on serotonin-dependent aggregation and serotonin transport in platelets of patients with migraine,” Bulletin of Experimental Biology and Medicine, vol. 130, no. 7, pp. 633–635, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. S. Medeiros and J. B. Calixto, “Influence of calcium entry blockers and calmodulin inhibitors on 5-hydroxytryptamine-, potassium- and calcium-induced contractions in human umbilical artery in-vitro,” Journal of Pharmacy and Pharmacology, vol. 43, no. 6, pp. 411–416, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Kariya, S. Isozaki, Y. Masubuchi, T. Suzuki, and S. Narimatsu, “Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine,” Biochemical Pharmacology, vol. 50, no. 10, pp. 1645–1650, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. T.-S. Chang and V. C.-H. Lin, “Melanogenesis inhibitory activity of two generic drugs: cinnarizine and trazodone in mouse B16 melanoma cells,” International Journal of Molecular Sciences, vol. 12, no. 12, pp. 8787–8796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. F. Marti Masso, J. A. Obeso, N. Carrera, and J. M. Martinez-Lage, “Aggravation of Parkinson's disease by cinnarizine,” Journal of Neurology Neurosurgery and Psychiatry, vol. 50, no. 6, pp. 804–805, 1987. View at Publisher · View at Google Scholar · View at Scopus
  22. Cinnarizine.Drugs.com—Drug Information, 2013, http://www.drugs.com/international/cinnarizine.html.
  23. Cinnarizine. Brand name. Drugs update.com. 2013, http://www.drugsupdate.com/brand/showavailablebrands/467.
  24. H. Ogata, N. Aoyagi, N. Kaniwa et al., “Gastric acidity dependent bioavailability of cinnarizine from two commercial capsules in healthy volunteers,” International Journal of Pharmaceutics, vol. 29, no. 2-3, pp. 113–120, 1986. View at Publisher · View at Google Scholar · View at Scopus
  25. A. A.-W. Shahba, K. Mohsin, and F. K. Alanazi, “Novel self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of cinnarizine: design, optimization, and in-vitro assessment,” AAPS PharmSciTech, vol. 13, no. 3, pp. 967–977, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. P. S. Burton, J. T. Goodwin, T. J. Vidmar, and B. M. Amore, “Predicting drug absorption: how nature made it a difficult problem,” Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 3, pp. 889–895, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Tokumura, H. Ueda, Y. Tsushima et al., “Inclusion complex of cinnarizine with β-cyclodextrin in aqueous solution and in solid state,” Journal of Inclusion Phenomena, vol. 2, no. 3-4, pp. 511–521, 1984. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Tokumura, M. Nanba, Y. Tsushima et al., “Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent,” Journal of Pharmaceutical Sciences, vol. 75, no. 4, pp. 391–394, 1986. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Tokumura, Y. Tsushima, K. Tatsuishi, M. Kayano, Y. Machida, and T. Nagai, “Enhancement of the bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with L-isoleucine as a competing agent,” Chemical and Pharmaceutical Bulletin, vol. 34, no. 3, pp. 1275–1279, 1986. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Tokumura, Y. Tsushima, K. Tatsuishi, M. Kayano, Y. Machida, and T. Nagai, “Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs,” Journal of Pharmaceutical Sciences, vol. 76, no. 4, pp. 286–288, 1987. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Järvinen, K. Järvinen, N. Schwarting, and V. J. Stella, “β-Cyclodextrin derivatives, SBE4-β-CD and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs,” Journal of Pharmaceutical Sciences, vol. 84, no. 3, pp. 295–299, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. B. S. Kalava, M. Demirel, and Y. Yazan, “Physicochemical characterization and dissolution properties of cinnarizine solid dispersion,” Turkish Journal of Pharmaceutical Sciences, vol. 2, no. 2, pp. 51–62, 2005. View at Google Scholar
  33. D. M. Mehta, P. B. Parejiya, B. S. Barot, and P. K. Shelat, “Investigation of the drug release modulating effect of acidifiers in modified release oral formulation of cinnarizine,” Asian Journal of Pharmaceutical Sciences, vol. 7, no. 3, pp. 193–201, 2012. View at Google Scholar · View at Scopus
  34. R. P. Patel and A. Suthar, “Formulation and process optimization of cinnarizine fast-release tablets,” Pharmaceutical Technology, vol. 33, no. 8, pp. 53–59, 2009. View at Google Scholar · View at Scopus
  35. M. Nagar and A. V. Yadav, “Cinnarizine orodispersible tablets: a chitosan based fast mouth dissolving technology,” International Journal of PharmTech Research, vol. 1, no. 4, pp. 1079–1091, 2009. View at Google Scholar · View at Scopus
  36. B. Basu, A. Bagadiya, S. Makwana, V. Vipul, D. Batt, and A. Dharamsi, “Formulation and evaluation of fast dissolving tablets of cinnarizine using superdisintegrant blends and subliming material,” Journal of Advanced Pharmaceutical Technology and Research, vol. 2, no. 4, pp. 266–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. N. G. Raghavendra Rao, U. Kulkarni, and B. S. Patil, “Design and development of fast dissolving Cinnarizine tablets by sublimation technique,” Research Journal of Pharmacy and Technology, vol. 4, no. 4, pp. 585–588, 2011. View at Google Scholar · View at Scopus
  38. B. P. Patel, J. K. Patel, G. C. Rajput, and R. S. Thakor, “Formulation and evaluation of mouth dissolving tablets of cinnarizine,” Indian Journal of Pharmaceutical Sciences, vol. 72, no. 4, pp. 522–525, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Heer, G. Aggarwal, and S. L. H. Kumar, “Development of fast dissolving oral films and tablets of cinnarizine: effect of superdisintegrants,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 2, pp. 186–191, 2014. View at Google Scholar · View at Scopus
  40. N. Thomas, R. Holm, T. Rades, and A. Müllertz, “Characterising lipid lipolysis and its implication in lipid-based formulation development,” The AAPS Journal, vol. 14, no. 4, pp. 860–871, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. B. K. Nanjwade, D. J. Patel, R. A. Udhani, and F. V. Manvi, “Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs,” Scientia Pharmaceutica, vol. 79, no. 4, pp. 705–727, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. K. W. Lee, C. J. Porter, and B. J. Boyd, “The effect of administered dose of lipid-based formulations on the In Vitro and In Vivo performance of cinnarizine as a model poorly water-soluble drug,” Journal of Pharmaceutical Sciences, vol. 102, no. 2, pp. 565–578, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. A. T. Larsen, A. Ogbonna, R. Abu-Rmaileh, B. Abrahamsson, J. Østergaard, and A. Müllertz, “SNEDDS containing poorly water soluble cinnarizine; development and In vitro characterization of dispersion, digestion and solubilization,” Pharmaceutics, vol. 4, no. 4, pp. 641–665, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. A. T. Larsen, A. G. Ohlsson, B. Polentarutti et al., “Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation,” European Journal of Pharmaceutical Sciences, vol. 48, no. 1-2, pp. 339–350, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. A. T. Larsen, P. Åkesson, A. Juréus et al., “Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis,” Pharmaceutical Research, vol. 30, no. 12, pp. 3101–3113, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. B. J. Boyd, S.-M. Khoo, D. V. Whittaker, G. Davey, and C. J. H. Porter, “A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats,” International Journal of Pharmaceutics, vol. 340, no. 1-2, pp. 52–60, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Vithlani, S. Sarraf, and C. S. Chaw, “Formulation and in vitro evaluation of self-emulsifying formulations of Cinnarizine,” Drug Development and Industrial Pharmacy, vol. 38, no. 10, pp. 1188–1194, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. K. W. Y. Lee, C. J. H. Porter, and B. J. Boyd, “Gastric pre-processing is an important determinant of the ability of medium-chain lipid solution formulations to enhance oral bioavailability in rats,” Journal of Pharmaceutical Sciences, vol. 102, no. 11, pp. 3957–3965, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Shi, H. Chen, X. Lin, and X. Tang, “Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion,” International Journal of Pharmaceutics, vol. 383, no. 1-2, pp. 264–270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Yasir and S. Rai, “Cinnarizine loaded lipid based system: preparation, optimization and in-vitro evaluation,” IOSR Journal of Pharmacy, vol. 2, no. 5, pp. 47–56, 2012. View at Google Scholar
  51. P. J. Sassene, M. M. Knopp, J. Z. Hesselkilde et al., “Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate,” Journal of Pharmaceutical Sciences, vol. 99, no. 12, pp. 4982–4991, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. L. Christiansen, R. Holm, J. Kristensen et al., “Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS),” European Journal of Pharmaceutical Sciences, vol. 57, no. 1, pp. 164–172, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. P. C. Christophersen, M. L. Christiansen, R. Holm et al., “Fed and fasted state gastro-intestinal in vitro lipolysis: in vitro in vivo relations of a conventional tablet, a SNEDDS and a solidified SNEDDS,” European Journal of Pharmaceutical Sciences, vol. 57, no. 1, pp. 232–239, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Kayaert, M. Anné, and G. van den Mooter, “Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads,” Journal of Pharmacy and Pharmacology, vol. 63, no. 11, pp. 1446–1453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Shanmugam and R. Banerjee, “Nanostructured self assembled lipid materials for drug delivery and tissue engineering,” Therapeutic Delivery, vol. 2, no. 11, pp. 1485–1516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. G. A. Kossena, W. N. Charman, B. J. Boyd, and C. J. H. Porter, “A novel cubic phase of medium chain lipid origin for the delivery of poorly water soluble drugs,” Journal of Controlled Release, vol. 99, no. 2, pp. 217–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. T.-H. Nguyen, T. Hanley, C. J. H. Porter, and B. J. Boyd, “Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration,” Journal of Controlled Release, vol. 153, no. 2, pp. 180–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. T.-H. Nguyen, T. Hanley, C. J. H. Porter, and B. J. Boyd, “Nanostructured reverse hexagonal liquid crystals sustain plasma concentrations for a poorly water-soluble drug after oral administration,” Drug Delivery and Translational Research, vol. 1, no. 6, pp. 429–438, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Machida, K. Inouye, T. Tokumura, M. Iwata, and T. Nagai, “Preparation and evaluation of intragastric buoyant preparations,” Drug Design and Delivery, vol. 4, no. 2, pp. 155–161, 1989. View at Google Scholar · View at Scopus
  60. J. Varshosaz, M. Tabbakhian, and M. Zahrooni, “Development and characterization of floating microballoons for oral delivery of cinnarizine by a factorial design,” Journal of Microencapsulation, vol. 24, no. 3, pp. 253–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. R. C. Nagarwal, D. N. Ridhurkar, and J. K. Pandit, “In vitro release kinetics and bioavailability of gastroretentive cinnarizine hydrochloride tablet,” AAPS Pharmaceutical Sciences and Technology, vol. 11, no. 1, pp. 294–303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. K. N. Tarkase, M. K. Tarkase, M. D. Dokhe, and V. S. Wagh, “Formulation, optimization and comparative evaluation of Gastroretentive drug delivery system of Cinnarizine and Domperidone maleate floating tablet,” International Journal of Pharmaceutical Sciences Review and Research, vol. 17, no. 2, pp. 29–35, 2012. View at Google Scholar · View at Scopus
  63. A. Patnaik and S. Mantry, “Formulation & evaluation of gastroretensive floating microsphere of CINNARiZINE,” Asian Journal of Pharmaceutical and Clinical Research, vol. 5, no. 4, pp. 100–109, 2012. View at Google Scholar · View at Scopus
  64. P. Kumar and M. Bhatia, “Functionalization of chitosan/methylcellulose interpenetrating polymer network microspheres for gastroretentive application using central composite design,” PDA Journal of Pharmaceutical Science and Technology, vol. 64, no. 6, pp. 497–506, 2010. View at Google Scholar · View at Scopus
  65. J. K. Patel, P. S. Patil, and V. B. Sutariya, “Formulation and characterization of mucoadhesive microparticles of cinnarizine hydrochloride using supercritical fluid technique,” Current drug delivery, vol. 10, no. 3, pp. 317–325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. I. Singh and V. Rana, “Iron oxide induced enhancement of mucoadhesive potential of Eudragit RLPO: formulation, evaluation and optimization of mucoadhesive drug delivery system,” Expert Opinion on Drug Delivery, vol. 10, no. 9, pp. 1179–1191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Verma, K. Nagpal, S. K. Singh, and D. N. Mishra, “Unfolding type gastroretentive film of cinnarizine based on ethyl cellulose and hydroxypropylmethyl cellulose,” International Journal of Biological Macromolecules, vol. 64, pp. 347–352, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. M. A. Alhnan, S. Murdan, and A. W. Basit, “Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability,” International Journal of Pharmaceutics, vol. 416, no. 1, pp. 55–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Togha, F. Taghdiri, S. R. Jahromi, and F. Refaeian, “Cinnarizine for the prophylaxis of migraine associated vertigo: a retrospective study,” SpringerPlus, vol. 3, article 231, 2014. View at Google Scholar
  70. R. Salari, H. Hatefi, E. Abbasi, H.-R. Soltani-Gerdefaramarzi, and M.-H. Mortazavi, “Comparison of therapeutic effects of alprazolam and cinnarizine in patients with idiopathic tinnitus: a clinical trial study,” Journal of Mazandaran University of Medical Sciences, vol. 23, no. 106, pp. 11–18, 2013. View at Google Scholar · View at Scopus
  71. M. Togha, R. A. Malamiri, N. Rashidi-Ranjbar, S. Asa, F. Mahvelati, and M. R. Ashrafi, “Efficacy and safety of cinnarizine in the prophylaxis of migraine headaches in children: an open, randomized comparative trial with propranolol,” Acta Neurologica Belgica, vol. 112, no. 1, pp. 51–55, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Tosoni, F. Lodi-Rizzini, M. Cinquini et al., “A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: a retrospective study of 47 patients,” Clinical and Experimental Dermatology, vol. 34, no. 2, pp. 166–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. T. Mansoureh, M. Rahmat Jirde, K. Nilavari, H. Ashrafian, S. Razeghi, and L. Kohan, “Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate,” Journal of Headache and Pain, vol. 9, no. 2, pp. 77–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Togha, H. Ashrafian, and P. Tajik, “Open-label trial of cinnarizine in migraine prophylaxis,” Headache, vol. 46, no. 3, pp. 498–502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. O. P. Dall'Igna, A. B. L. Tort, D. O. Souza, and D. R. Lara, “Cinnarizine has an atypical antipsychotic profile in animal models of psychosis,” Journal of Psychopharmacology, vol. 19, no. 4, pp. 342–346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. C. Tosoni, F. Lodi-Rizzini, L. Bettoni et al., “Cinnarizine is a useful and well-tolerated drug in the treatment of acquired cold urticaria (ACU),” European Journal of Dermatology, vol. 13, no. 1, pp. 54–56, 2003. View at Google Scholar · View at Scopus
  77. C. P. Pianese, L. O. V. Hidalgo, R. H. González et al., “New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study,” Otology and Neurotology, vol. 23, no. 3, pp. 357–363, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Shupak, I. Doweck, C. R. Gordon, and O. Spitzer, “Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study,” Clinical Pharmacology and Therapeutics, vol. 55, no. 6, pp. 670–680, 1994. View at Publisher · View at Google Scholar · View at Scopus
  79. I. Doweck, C. R. Gordon, O. Spitzer, Y. Melamed, and A. Shupak, “The vestibulo-ocular reflex (VOR) under the influence of cinnarizine,” Journal of Vestibular Research: Equilibrium and Orientation, vol. 4, no. 3, pp. 215–220, 1994. View at Google Scholar · View at Scopus
  80. R. Hausler, E. Sabani, and M. Rohr, “Effect of cinnarizine on various types of vertigo. Clinical and electronystagmographic results of a double-blind study,” Acta Oto-Rhino-Laryngologica Belgica, vol. 43, no. 2, pp. 177–185, 1989. View at Google Scholar · View at Scopus
  81. B. Saletu and J. Grunberger, “Antihypoxidotic and nootropic drugs: proof of their encephalotropic and pharmacodynamic properties by quantitative EEG investigations,” Progress in Neuro-Psychopharmacology, vol. 4, no. 4-5, pp. 469–489, 1980. View at Publisher · View at Google Scholar · View at Scopus
  82. M. B. Emanuel, J. A. Chamberlain, S. Whiting, B. G. Rigden, and A. H. Craven, “Cinnarizine in the treatment of chronic asthma,” British Journal of Clinical Pharmacology, vol. 7, no. 2, pp. 189–195, 1979. View at Publisher · View at Google Scholar · View at Scopus